Evommune hosts webcast to discuss EVO570 licensing deal

EVMN•2026-11-05

Evommune will host a prerecorded webcast on EVO570 at 8:30 a.m. ET on Nov. 5, 2026, covering licensing terms, planned rheumatoid arthritis development and its role in the immunology pipeline.

1. Webcast details

Evommune will host a prerecorded webcast on EVO570 at 8:30 a.m. ET on Nov. 5, 2026. Management will discuss the oral VAV1-directed molecular glue degrader’s licensing terms, planned rheumatoid arthritis development and role in the immunology pipeline.

Evommune hosts webcast to discuss EVO570 licensing deal

1. Webcast details

Related News

Chimera declares fourth-quarter 2026 preferred dividends of up to $0.6343 per share

McDonald's: Mizuho raises target price to $280 from $260

Vishay forecasts fourth-quarter revenue of $975 million to $1.01 billion

Imperial Oil: Scotiabank raises target price to C$186 from C$183

Bullish October trading volume falls 22% month on month